Investigational drug · Phase 2
Foralumab Nasal
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
9
Any phase or sponsor naming "Foralumab Nasal"
First trial start
2025
May 19, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Foralumab Nasal", any sponsor or status.
Conditions studied
As listed on its trial records.
- ALS (Amyotrophic Lateral Sclerosis)
- ALS - Amyotrophic Lateral Sclerosis
- ALS
- Multiple System Atrophy
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Foralumab Nasal" as an intervention, largest first.
Tiziana Life Sciences LTDIndustry
NCT06890923 · 55 participants (planned) · Start Mar 4, 2025 · Primary completion Apr 30, 2026
Drug: Foralumab TZLS-401 100 µg · For: Non-Active Secondary Progressive Multiple Sclerosis
Sites: Boston, Massachusetts
Tiziana Life Sciences LTDIndustry
NCT06292923 · 54 participants · Start Nov 15, 2023 · Primary completion Sep 17, 2026
Drug: Foralumab · For: Secondary Progressive Multiple Sclerosis
Sites: North Haven, Connecticut; Baltimore, Maryland; Boston, Massachusetts · 8 sites in all
- The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal ForalumabEnrolling by invitation
Tiziana Life Sciences LTDIndustry
NCT07688239 · 44 participants (planned) · Start Sep 23, 2026 · Primary completion Jul 2027
Drug: Foralumab Nasal; Placebo · For: ALS (Amyotrophic Lateral Sclerosis); ALS - Amyotrophic Lateral Sclerosis; ALS
Sites: Davie, Florida; Chicago, Illinois; Boston, Massachusetts · 4 sites in all
Tiziana Life Sciences LTDIndustry
NCT06879067 · 27 participants · Start Nov 12, 2018 · Primary completion Jul 23, 2019
Drug: Placebo; Foralumab Nasal · For: Safety; Tolerability
Sites: Boston, Massachusetts
- Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's DiseaseRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT06489548 · 16 participants (planned) · Start Sep 16, 2025 · Primary completion Jun 2026
Drug: Foralumab TZLS-401 50 µg; Foralumab TZLS-401 100 µg · For: Dementia; Alzheimers Disease; Mild Cognitive Impairment Due to Alzheimer's Disease
Sites: Boston, Massachusetts
Tiziana Life Sciences LTDIndustry
NCT06868628 · 5 participants (planned) · Start May 19, 2025 · Primary completion Apr 1, 2027
Drug: Foralumab Nasal · For: Multiple System Atrophy
Sites: Boston, Massachusetts
Tiziana Life Sciences LTDIndustry
NCT04983446 · 0 participants · Start Apr 30, 2022 · Primary completion Oct 30, 2022
Drug: Foralumab · For: Covid19; COVID-19 Lower Respiratory Infection; COVID-19 Respiratory Infection
- Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MSWithdrawn
Tiziana Life Sciences LTDIndustry
NCT05029609 · 0 participants · Start Oct 2021 · Primary completion Nov 2022
Drug: Intranasal Foralumab Solution; Placebo · For: Primary Progressive Multiple Sclerosis; Secondary Progressive Multiple Sclerosis; Multiple Sclerosis
Tiziana Life Sciences LTDIndustry
NCT06802328
Drug: Foralumab TZLS-401 50 µg · For: Non-Active Secondary Progressive Multiple Sclerosis
Sites: Boston, Massachusetts
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for ALS (Amyotrophic Lateral Sclerosis)
- Test drug CB03-154 groupPhase 32 trials
Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.